Christopher Elnan Kvistad,
Halvor Næss,
Bernt Harald Helleberg,
Titto Idicula,
Guri Hagberg,
Linn Marie Nordby
m.fl.:
Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial
Lancet Neurology 04. mai 2022
DOI
Mary-Helen Søyland,
Arnstein Tveiten,
Agnethe Eltoft,
Halvor Øygarden,
Torunn Varmdal,
Bent Indredavik
m.fl.:
Wake-up stroke and unknown-onset stroke; occurrence and characteristics from the nationwide Norwegian Stroke Register
European Stroke Journal 2022
ARKIV /
DOI
Melinda Berg Roaldsen,
Agnethe Eltoft,
Tom Wilsgaard,
Hanne Christensen,
Stefan T. Engelter,
Bent Indredavik
m.fl.:
Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial.
Agnethe Eltoft,
Tom Wilsgaard,
Melinda Berg Roaldsen,
Mary-Helen Søyland,
Erik Lundström,
Jesper Petersson
m.fl.:
Statistical analysis plan for the randomized controlled trial Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST)
Melinda Berg Roaldsen,
Haakon Lindekleiv,
Agnethe Eltoft,
Mirza Jusufovic,
Mary-Helen Søyland,
Jesper Petersson
m.fl.:
Tenecteplase in wake-up ischemic stroke trial: Protocol for a randomized-controlled trial
International Journal of Stroke 14. januar 2021
ARKIV /
DOI
Agnethe Eltoft,
Kjell Arne Arntzen,
Tom Wilsgaard,
John-Bjarne Hansen,
Ellisiv B. Mathiesen,
Stein Harald Johnsen
:
Joint Effect of Carotid Plaque and C-Reactive Protein on First-Ever Ischemic Stroke and Myocardial Infarction?
Journal of the American Heart Association (JAHA) 2018
ARKIV /
DOI
Agnethe Eltoft,
Kjell Arne Arntzen,
Tom Wilsgaard,
Ellisiv B. Mathiesen,
Stein Harald Johnsen
:
Interleukin-6 is an independent predictor of progres
sive atherosclerosis in the
carotid artery: The Tromsø Study
Agnethe Eltoft,
Kjell Arne Arntzen,
John-Bjarne Hansen,
Tom Wilsgaard,
Ellisiv B. Mathiesen,
Stein Harald Johnsen
:
C-reactive protein in atherosclerosis - A risk marker but not a causal factor? A 13-year population-based longitudinal study: The Tromsø study
C-reactive protein in atherosclerosis - A risk marker but not a causal factor? A 13-year population-based longitudinal study: The Tromsø study.
Danni Zheng,
Shoichiro Sato,
Hisatomi Arima,
Emma Heeley,
Candice Delcourt,
Yongjun Cao
m.fl.:
Estimated GFR and the effect of intensive blood pressure lowering after acute intracerebral hemorrhage
American Journal of Kidney Diseases 2016
DOI
Karl Øyvind Mikalsen,
Marte Stoksvik,
Karoline Skrøder,
Agnethe Eltoft,
Tommy Skar
:
Universitetssykehuset Nord-Norge bruker kunstig intelligens for bedre behandling av slag og blodpropp
10. september 2024
Ole Morten Rønning,
Maria Kristin Carlsson,
Hege Ihle-Hansen,
Anne Hege Aamodt,
Arnstein Tveiten,
Agnethe Eltoft
m.fl.:
Overvåkning etter akutt hjerneslag bør bli bedre
Tidsskrift for Den norske legeforening 2022
DOI
Anne Hege Aamodt,
Erik Taubøll,
Tom Eich Ele,
Luis Georg Romundstad,
Angelika Sorteberg,
Sean Ciaran Wallace
m.fl.:
Brain monitoring in hospitals needs to be strengthened
Tidsskrift for Den norske legeforening 2021
DOI
Agnethe Eltoft
:
C-reactive protein and other circulating biomarkers in carotid
atherosclerosis and cardiovascular disease
The Tromsø Study 1994-2013
UiT Norges arktiske universitet 2018
Agnethe Eltoft,
Kjell Arne Arntzen,
Tom Wilsgaard,
Ellisiv B. Mathiesen,
Stein Harald Johnsen
:
Corrigendum to “Interleukin-6 is an independent predictor of progressive atherosclerosis in the carotid artery: The Troms? study” [Atherosclerosis 271 (April 2018) 1-8]